Recent findings demonstrate that anti-NF-κB nanotherapy has the potential to inhibit the progression, metastasis, and chemotherapy resistance in various tumors such as CRC [154], NSCLC [155], pancreatic cancer [156], breast cancer [157,158], GBM [159], adult T-cell leukemia/lymphoma (ATLL) [160], and melanoma [161]. This evidence concerns the gene NFKB1 and breast carcinoma.